IP Library Patent Application 11516210
Patent Application
App. No. 11/516,210

Diagnostic markers of wound infection II

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/516,210
Abstract

The present invention relates to a method of diagnosis or prognosis of a mammalian wound infection, said method comprising the step of measuring the level of at least on angiogenic factor in a sample of wound fluid. The preferred angiogenic growth factors are angiogenin and vascular endothelial growth factor (VEGF). The present invention also provides devices (e.g. biosensors) for use in such methods, and methods and products for diagnosing and treating infected wounds.

Claims (12)

1 . A method of diagnosis or prognosis of a mammalian wound infection, said method comprising the step of measuring the level of at least one angiogenic factor in a sample of wound fluid.

2 . A method according to claim 1 , wherein the angiogenic growth factor is selected from the group consisting of acidic fibroblast growth factor (FGF-1), granulocyte colony stimulating factor (G-CSF), basic fibroblast growth factor (FGF-2), hepatocyte growth factor scatter factor (HGF/SF), vascular endothelial growth factor, vascular permeability factor (VEGF/VPF), pleiotrophin transforming growth factor-α (TGFα), proliferin transforming growth factor-β (TGFβ), follistatin tumor necrosis factor-α (TNF-α), placental growth factor (PlGF), angiogenin midkine interleukin-3 (IL-3), platelet-derived growth factor-BB (PDGF-BB), interleukin-8 (IL-8), fractalkine platelet-derived endothelial growth factor (PD-ECGF), and combinations thereof.

3 . A method according to claim 2 , wherein the angiogenic growth factor is selected from the group consisting of angiogenin, VEGF, and combinations thereof.

4 . A method according to claim 3 , wherein the method is an in vitro method carried out on a sample of wound fluid that has been removed from a patient.

5 . A method according to claim 3 , wherein said step of measuring comprises contacting the sample of wound fluid with an immunological binding partner for an angiogenic factor.

6 . A method according to claim 5 , further comprising comparing the measured level of said one or more angiogenic factors in said sample of wound fluid with a reference level characteristic of a non-infected wound.

7 . A method according to claim 6 , wherein the method comprises sampling the wound fluid at intervals of from about 1 hour to about 24 hours and measuring the level of said one or more angiogenic factors in the samples obtained at said intervals.

8 . A method according to claim 6 , wherein the method further comprises measuring a total protein content of the wound fluid and normalising the measured levels of said one or more angiogenic factors to constant total protein content.

9 . A method for the treatment of a mammalian wound comprising the steps of measuring the level of one or more angiogenic factors selected from the group consisting of angiogenin, VEGF, and combinations thereof in a sample of wound fluid, and applying an antimicrobial wound dressing to the wound selectively if the presence or level of said marker is indicative of wound infection wherein the step of measuring the level of one or more angiogenic factors comprises contacting the sample of wound fluid with an immunological binding partner for an angiogenic factor and comparing the measured level of said one or more angiogenic factors in said sample of wound fluid with a reference level characteristic of a non-infected wound.

10 . A method according to claim 9 , further comprising applying a wound dressing that is substantially free of antimicrobial agents to the wound if the said presence or level is indicative of absence of wound infection.

11 . A method according to claim 9 , wherein the method comprises sampling the wound fluid at intervals, for example at intervals of from 1 hour to 24 hours, and selecting an antimicrobial or non-antimicrobial dressing to treat the wound at said intervals in response to the measured presence or level of said marker.

12 . A method according to claim 11 , wherein the antimicrobial wound dressing is applied to the wound if said level is increasing over time, and the non-antimicrobial dressing is applied to the wound if said level is decreasing over time.

Assignments (8)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Feb 6, 2017
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: KCI LICENSING, INC., AS GRANTOR; TECHNIMOTION, LLC, A DELAWARE LIMITED LIABILITY COMPANY, AS GRANTOR; SYSTAGENIX WOUND MANAGEMENT (US), INC., A DELAWARE CORPORATION, AS GRANTOR
Reel/Frame 041395/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2014
From: SYSTAGENIX WOUND MANAGEMENT (US), INC.
To: WOUNDCHECK LABORATORIES (US), INC.
Reel/Frame 033682/0278 →
SECURITY AGREEMENT Recorded Oct 29, 2013
From: SYSTAGENIX WOUND MANAGEMENT (US), INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 031508/0011 →
RELEASE OF SECURITY INTEREST Recorded Oct 28, 2013
From: J.P. MORGAN EUROPE LIMITED
To: SYSTAGENIX WOUND MANAGEMENT (US), INC.
Reel/Frame 031506/0186 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2010
From: ETHICON, INC.; JOHNSON & JOHNSON MEDICAL LIMITED
To: SYSTAGENIX WOUND MANAGEMENT IP CO. B.V.
Reel/Frame 024563/0344 →
SECURITY AGREEMENT Recorded Jan 30, 2009
From: SYSTAGENIX WOUND MANAGEMENT (US), INC.
To: J.P. MORGAN EUROPE LIMITED
Reel/Frame 022177/0037 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2009
From: ETHICON, INC.; JOHNSON & JOHNSON MEDICAL LIMITED
To: SYSTAGENIX WOUND MANAGEMENT (US), INC.
Reel/Frame 022071/0762 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2006
From: CLARK, RACHAEL L.; CULLEN, BREDA M.
To: ETHICON, INC.
Reel/Frame 018280/0590 →